CLARITIN RAPID DISSOLVE TABLET (ORALLY DISINTEGRATING)
Страна: Канада
Език: английски
Източник: Health Canada
Данни за продукта
(SPC)
30-04-2020
Понастоящем някои документи за този продукт не са налични, можете да изпратите заявка до нашата служба за клиенти и ние ще ви уведомим веднага щом успеем да ги получим.
Изпрати заяв.
Изпрати заяв.
Активна съставка:
LORATADINE
Предлага се от:
BAYER INC
АТС код:
R06AX13
INN (Международно Name):
LORATADINE
дозиране:
10MG
Лекарствена форма:
TABLET (ORALLY DISINTEGRATING)
Композиция:
LORATADINE 10MG
Начин на приложение:
ORAL
Броя в опаковка:
8/10/30
Вид предписание :
OTC
Терапевтична област:
SECOND GENERATION ANTIHISTAMINES
Каталог на резюме:
Active ingredient group (AIG) number: 0120416001; AHFS:
Статус Оторизация:
APPROVED
Дата Оторизация:
1998-04-06
Данни за продукта
_CLARITIN ALLERGY, CLARITIN RAPID DISSOLVE, CLARITIN KIDS RAPID
DISSOLVE & CLARITIN KIDS_
_Page 1 of 40_
PRODUCT MONOGRAPH
CLARITIN
®
ALLERGY
Loratadine Tablets USP 10 mg
CLARITIN
®
RAPID DISSOLVE™
Loratadine Orally Disintegrating Tablets USP 10 mg
Loratadine Orally Disintegrating Tablets USP 5 mg
CLARITIN
®
KIDS RAPID DISSOLVE™
Loratadine Orally Disintegrating Tablets USP 5 mg
CLARITIN KIDS
®
Loratadine Oral Solution USP 1 mg/mL
Histamine H
1
receptor antagonist
Bayer Inc.
2920 Matheson Blvd. E
Mississauga, ON
L4W 5R6
Date of Revision:
April 30
th
, 2020
Submission Control No: 228699
® TM see www.bayer.ca/tm-mc
_CLARITIN ALLERGY, CLARITIN RAPID DISSOLVE, CLARITIN KIDS RAPID
DISSOLVE & CLARITIN KIDS_
_Page 2 of 40_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION.....................................................3
SUMMARY PRODUCT INFORMATION
...............................................................................3
INDICATIONS AND CLINICAL
USE.....................................................................................3
CONTRAINDICATIONS
..........................................................................................................4
WARNINGS AND
PRECAUTIONS.........................................................................................4
ADVERSE
REACTIONS...........................................................................................................5
DRUG INTERACTIONS
...........................................................................................................9
DOSAGE AND
ADMINISTRATION.......................................................................................9
OVERDOSAGE
.......................................................................................................................11
ACTION AND CLINICAL PHARMACOLOGY
...................................................................11
STORAGE AND
STABILITY.................................................................................................15
SPECIAL HANDL
Прочетете целия документ
